Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPOCD: Minocycline for Postoperative Cognitive Dysfunction and Delirium
NCT02928692Phase 3Unknown
- Sponsor
- Renji Hospital
- Start
- Nov 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of minocycline in Post-operative cognitive dysfunction (POCD) and postoperative delirium (POD) (3 arms), sponsored by Renji Hospital. Primary endpoints: Postoperative Cognitive Dysfunction incidence at 7 days and Postoperative Delirium incidence. Status: unknown.
02
Drugs
minocycline
03
Conditions
Post-operative cognitive dysfunction (POCD)postoperative delirium (POD)
Beyond the preview
Go deeper on NCT02928692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928692.